Lysosomal Therapeutics

company

About

Lysosomal Therapeutics deliver cures for neurodegenerative diseases.

  • 1 - 10

Highlights

Details

Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.

Investments

Number of Investments
Number of Lead Investments
1
0
Lysosomal Therapeutics has made 1 investments. Their most recent investment was on Mar 5, 2015, when Aura Biosciences raised $21M.
Date Company Name
Round Money Raised Industry Lead Investor
Mar 5, 2015 Aura Biosciences
Series B $21M Biotechnology